NBB, one possible event that could drive interest in RVX would be a licensing deal with a company by Boehringer Ingelheim for production, marketing, sales and distribution in the EU countries and perhaps beyond. I can't help but speculate that Christoph Boehringer with his CV Ventures investment in RVX is not some sort of informal communication conduit to the Boehringer Ingelheim board or even senior management.

Just speculation on my part but it seems like a natural connection.

I'm also wondering if the "what appears to be high levels of attendance and presentations" by RVX at conferences combined with what I sense is a real growth in momentum in epigenetics that perhaps there might be some trigger point that could cause an upsurge in widespread interest. I guess that will be successful top line BoM results but we've seen independent positive research papers on apabetalone previously and perhaps there will be more before the top lines?

Finally, from the press release on Oct 22 ..."The BETonMACE trial is expected to be complete around the end of 2018 with the topline results expected shortly thereafter".

That sounds good to me but I think optimistic. The underline is mine.

Toinv